Wire · opportunities
Pfizer steps into in vivo CAR T space with $2.6B licensing deal
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 November 2026 · Fusion42 review
Pfizer has entered an exclusive $2.6 billion licensing deal with Starna Therapeutics for three in vivo pre-IND CAR-T autoimmune programs, marking Pfizer's first move into the in vivo CAR-T space amid upcoming patent expirations.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You should now consider in vivo CAR-T as a viable autoimmune treatment path, as Pfizer's entry signals growing commercial validation and upcoming market openings in biotech therapies. Starna's technology could offer new partnership or competitive opportunities in CAR-T for autoimmune diseases.
◆ Coverage
1 source · 20 Nov 2026
◆ Related on Wire
◆ Topics